Ian Glassford

VP of Process Development & Scientific Excellence, Bristol Operations

Ian Glassford is Abzena’s Bristol, PA, Vice President of Process Development and Scientific Excellence. Ian leads a talented team of scientists across our process development services for bioconjugate drug programs. This includes antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), radionuclide antibody-conjugates (RACs) and radionuclide drug-conjugates (RDCs), cytokines, recombinant & conjugate vaccines, and nanoparticles.

Ian is part of Abzena’s Scientific Excellence group, bringing key technical expertise in chemistry and experience with clinical development to provide strategic support for synthetic chemistry and bioconjugation.

Ian has significant experience in the design and synthesis of structurally complex small molecules, the synthesis and handling of high potent compounds including R&D and early process development, and project management of small molecule and bioconjugate manufacturing projects, including planning and execution.

Ian started his career with GlaxoSmithKline where he worked as a medicinal chemist focused on synthesis of novel therapeutics utilizing structure and fragment-based design. Ian has a Ph.D. in organic chemistry from Temple University.

Discover Abzena Bristol, PA